Atherosclerosis
Volume 205, Issue 1 , Pages 181-185 , July 2009

A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity

  • Livia Lenzini

      Affiliations

    • Department of Clinical & Experimental Medicine, University of Padova, Italy
    • ,
  • Katia Antezza

      Affiliations

    • Department of Clinical & Experimental Medicine, University of Padova, Italy
    • ,
  • Brasilina Caroccia

      Affiliations

    • Department of Clinical & Experimental Medicine, University of Padova, Italy
    • ,
  • Robert L. Wolfert

      Affiliations

    • diaDexus San Francisco, USA
    • ,
  • Radoslaw Szczech

      Affiliations

    • Department of Hypertension & Diabetology, Medical University of Gdansk, Poland
    • ,
  • Maurizio Cesari

      Affiliations

    • Department of Clinical & Experimental Medicine, University of Padova, Italy
    • ,
  • Krzysztof Narkiewicz

      Affiliations

    • Department of Hypertension & Diabetology, Medical University of Gdansk, Poland
    • ,
  • Christopher J. Williams

      Affiliations

    • Department of Statistics, University of Idaho, Moscow, ID, USA
    • ,
  • Gian Paolo Rossi

      Affiliations

    • Department of Clinical & Experimental Medicine, University of Padova, Italy
    • Internal Medicine 4, University of Padova Medical School, Italy
    • Corresponding Author InformationCorresponding author at: Department of Clinical and Experimental Medicine, Clinica Medica 4 University Hospital, via Giustiniani 2, 35126 Padova, Italy. Tel.: +39 0 49 821 3304/2279; fax: +39 0 49 880 2252.

Received 27 May 2008 ,Revised 1 August 2008 ,Accepted 1 August 2008.

References 

  1. Stafforini DM, Tjoelker LW, McCormick SP, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999;274:7018–7024
  2. Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006;6:154–161
  3. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795
  4. Blencowe C, Hermetter A, Kostner GM, et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem. 1995;270:31151–31157
  5. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem. 1987;262:4223–4230
  6. Stafforini DM, McIntyre TM, Carter ME, et al. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215–4222
  7. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923–931
  8. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–1155
  9. Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  10. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842
  11. Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–1908
  12. Oei HH, van dM I, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation. 2005;111:570–575
  13. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53:1440–1447
  14. Sabatine MS, Morrow DA, O’Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2463–2469
  15. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523–2529
  16. Guerra R, Zhao B, Mooser V, et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38:2281–2288
  17. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996;97:2784–2791
  18. Hiramoto M, Yoshida H, Imaizumi T, et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke. 1997;28:2417–2420
  19. Yamada Y, Ichihara S, Fujimura T, et al. Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 1998;47:177–181
  20. Unno N, Nakamura T, Mitsuoka H, et al. Association of a G994→T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann Surg. 2002;235:297–302
  21. Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13:1341–1351
  22. Kruse S, Mao XQ, Heinzmann A, et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000;66:1522–1530
  23. Abuzeid AM, Hawe E, Humphries SE, et al. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis. 2003;168:283–288
  24. Cesari M, Narkiewicz K, De Toni R, et al. Heritability of plasma adiponectin levels and body mass index in twins. J Clin Endocrinol Metab. 2007;92:3082–3088
  25. Rossi GP, Narkiewicz K, Cesari M, et al. Genetic determinants of plasma ACE and renin activity in young normotensive twins. J Hypertens. 1999;17:647–655
  26. Cesari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol. 1999;19:1378–1386
  27. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419
  28. Williams CJ, Christian JC, Norton JA. TWINAN90: a FORTRAN program for conducting ANOVA-based and likelihood-based analyses of twin data. Comput Methods Programs Biomed. 1992;38:167–176
  29. Christian JC, Norton JA, Sorbel J, et al. Comparison of analysis of variance and maximum likelihood based path analysis of twin data: partitioning genetic and environmental sources of covariance. Genet Epidemiol. 1995;12:27–35
  30. Rossi GP, Maiolino G, Zanchetta M, et al. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol. 2006;48:1166–1174

PII: S0021-9150(08)00786-7

doi: 10.1016/j.atherosclerosis.2008.08.045

Atherosclerosis
Volume 205, Issue 1 , Pages 181-185 , July 2009

Article Tools

* Image Usage & Resolution